A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in
subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors.